NovAliX enters into cooperation agreement with Max-Planck spin-off - 03/27/2018
With exclusive rights to sell purified human 20S proteasome, a promising target for hematological malignancy treatment and cancer drug development, NovAliX will also provide structural biology ...
NovAliX and Pierre Fabre partner to provide access for NovAliX’ clients to Pierre Fabre’s extensive library of original fragments isolated from plants - 04/10/2018
NovAliX, a trusted provider of expert chemistry and biophysics services with cutting-edge screening techniques, will broaden the range of clients to access the bio-derived structurally diverse ...
Extraordinary first US edition of the NovAliX Conference “Biophysics in Drug Discovery" - 07/13/2018
5th NovAliX Conference “Biophysics in Drug Discovery” Boston, June 13-15, 2018
Last month, for the first time in its history the NovAliX Conference “Biophysi ...
NovAliX is a Contract Research Organization with chemistry and biophysical techniques. The integrated drug discovery solutions serve pharmaceutical, biotechnology companies and research institutions. Our commitment and reliability are much appreciated by a worldwide client base.